DE602005027883D1 - 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) - Google Patents

2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Info

Publication number
DE602005027883D1
DE602005027883D1 DE602005027883T DE602005027883T DE602005027883D1 DE 602005027883 D1 DE602005027883 D1 DE 602005027883D1 DE 602005027883 T DE602005027883 T DE 602005027883T DE 602005027883 T DE602005027883 T DE 602005027883T DE 602005027883 D1 DE602005027883 D1 DE 602005027883D1
Authority
DE
Germany
Prior art keywords
desulfated heparin
heparin
medicament
thrombocytopeny
heparine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005027883T
Other languages
German (de)
English (en)
Inventor
Jeanine M Walenga
Thomas Preston Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ParinGenix Inc
Original Assignee
ParinGenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ParinGenix Inc filed Critical ParinGenix Inc
Publication of DE602005027883D1 publication Critical patent/DE602005027883D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
DE602005027883T 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) Expired - Lifetime DE602005027883D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/974,566 US7468358B2 (en) 2004-06-16 2004-10-27 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
PCT/US2005/039011 WO2006047755A2 (en) 2004-10-27 2005-10-26 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome

Publications (1)

Publication Number Publication Date
DE602005027883D1 true DE602005027883D1 (de) 2011-06-16

Family

ID=36228513

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027883T Expired - Lifetime DE602005027883D1 (de) 2004-10-27 2005-10-26 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)

Country Status (9)

Country Link
US (1) US7468358B2 (enExample)
EP (1) EP1807095B1 (enExample)
JP (1) JP2008518090A (enExample)
AT (1) ATE507836T1 (enExample)
AU (1) AU2005299568A1 (enExample)
CA (1) CA2585640C (enExample)
DE (1) DE602005027883D1 (enExample)
ES (1) ES2366342T3 (enExample)
WO (1) WO2006047755A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009117677A2 (en) * 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
US8288515B2 (en) 2009-07-31 2012-10-16 Reliable Biopharmaceutical Corporation Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
NZ611316A (en) * 2010-12-01 2014-12-24 Univ Australian Histone inhibition
WO2013016181A1 (en) * 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
CA2862606C (en) 2012-02-02 2020-08-25 Reliable Biopharmaceutical Corporation An efficient and scalable process for the manufacture of fondaparinux sodium
LT2846809T (lt) * 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
AU2016234916A1 (en) * 2012-05-09 2016-11-17 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3265828B1 (en) 2015-03-03 2021-04-21 Laboratory Corporation of America Holdings Methods and systems for measuring serotonin in a sample
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
EP0651645B1 (en) * 1992-07-24 2002-02-27 Thomas P. Kennedy Medicament for inhibiting neutrophil elastase and cathepsin g
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US20080207895A1 (en) 2002-11-27 2008-08-28 Rosenberg Robert D Methods for synthesizing polysaccharides
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome

Also Published As

Publication number Publication date
CA2585640A1 (en) 2006-05-04
ATE507836T1 (de) 2011-05-15
EP1807095A2 (en) 2007-07-18
EP1807095B1 (en) 2011-05-04
WO2006047755A2 (en) 2006-05-04
ES2366342T3 (es) 2011-10-19
JP2008518090A (ja) 2008-05-29
WO2006047755A3 (en) 2007-02-01
EP1807095A4 (en) 2008-08-27
US7468358B2 (en) 2008-12-23
AU2005299568A1 (en) 2006-05-04
US20070123489A1 (en) 2007-05-31
CA2585640C (en) 2012-01-10

Similar Documents

Publication Publication Date Title
DE602005027883D1 (de) 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)
Gray et al. The anticoagulant and antithrombotic mechanisms of heparin
Longstaff et al. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems
WO2006023397A3 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
ATE523212T1 (de) Synthetische mehrschichtige hornhautstrukturen mit kollagen-fasern
ATE478867T1 (de) Substituierte quinazolinone verbindungen
BR0010380A (pt) Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
FR2648463B1 (fr) Polysaccharides sulfates, agent anticoagulant et agent anticomplementaire obtenus a partir de fucanes d'algues brunes et leur procede d'obtention
BR8304973A (pt) Mistura de polimero compativel
UA100378C2 (uk) Полімерна композиція, спосіб її виготовлення, виріб, спосіб його виготовлення та спосіб формування, застосування, спосіб підвищення швидкості текучості розплаву суміші та спосіб зменшення технологічного циклу формування виробу
NO983135L (no) Farmasaaytisk preparat
DE602006008985D1 (de) Zusammensetzung enthaltend oligosaccharide als lösliche ballaststoffe zur verwendung gegen muskelschwund
ES2296346T3 (es) Compuestos similares a la heparina, su preparacion y utilizacion para prevenir la trombosis arterial asociada a lesiones e intervenciones vasculares.
JP2008518090A5 (enExample)
Wang et al. The effect of hirudin modification of silk fibroin on cell growth and antithrombogenicity
Lee et al. Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
EA200802307A1 (ru) Бинарные смеси гиалуроновой кислоты и их терапевтическое применение
IL165807A0 (en) Process for preparing epimerized derivatives of k5polysaccharide with a very high degree of sulfati on and new epi k5-n,o-sulfated polysaccharide derivatives
ATE410147T1 (de) Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
BRPI0510780A (pt) partìcula de polìmero enxertada com polissacarìdeo, uso da mesma, composição para tratamento em lavagem de roupas, uso de uma composição para tratamento de roupas, e, método para tratar tecido
FR2860234B1 (fr) Nouveaux derives 666 du thioxylose
Richardson et al. Transient morphological and biochemical alterations of arterial proteoglycan during early wound healing
ATE399795T1 (de) Verfahren zur herstellung verbesserter dextran- hemoglobin konjugate
EA200700413A1 (ru) Ариламинкетоны, способ их получения, фармацевтические композиции, содержащие их, и их применение